Company: BDRX
Filing Date: 2025-04-29
Form Type: POS AM
Source: 0001214659-25-006581
Chunk: 25

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-29
Form: POS AM
Chunk 25
---
 gross proceeds to be raised by us from those sales, if any. As of January 15, 2025, there were 6,685,918,922 Ordinary Shares
outstanding. If all of the 358,750,000,000 Ordinary Shares offered for resale by the Selling Shareholder under this prospectus were issued
and outstanding as of January 15, 2025, such shares would represent approximately 98.2% of total number of Ordinary Shares outstanding.
The actual number of Depositary Shares issuable will vary depending on the then current market price of shares of our Depositary Shares
sold to the Selling Shareholder in this offering. To date, we have sold 17,398,000,000 Ordinary Shares under the Purchase Agreement.

The number of Depositary Shares
ultimately offered for sale by the Selling Shareholder for resale under this prospectus is dependent upon the number of Depositary Shares,
if any, we ultimately sell to the Selling Shareholder under the Purchase Agreement. Further, if and when we elect to sell Depositary Shares
to the Selling Shareholder pursuant to the Purchase Agreement, after the Selling Shareholder has acquired such shares, the Selling Shareholder
may resell all, some or none of such Depositary Shares at any time or from time to time in its discretion and at different prices.

The issuance of our Depositary
Shares to the Selling Shareholder pursuant to the Purchase Agreement will not affect the rights or privileges of our existing shareholders,
except that the economic and voting interests of each of our existing shareholders will be diluted. Although the number of Depositary
Shares that our existing shareholders own will not decrease, the Depositary Shares (and the underlying Ordinary Shares) owned by our existing
shareholders will represent a smaller percentage of our total outstanding Ordinary Shares after any such issuance.

| 16 |

The following table sets forth
the amount of gross proceeds we may receive from the Selling Shareholder from our sale of Purchase Shares that we may issue and sell to
the Selling Shareholder from time to time under the Purchase Agreement assuming that all such Purchase Shares are sold at varying purchase
prices designated below:

| Assumed Purchase 
 Price            
 Per Share (1)    |         |     | Total Number of Purchase Shares to be 
 Issued if                             
 Full Purchase                         |            |     | Percentage of Outstanding                                   
 Ordinary Shares After                                       
 Giving Effect to the Issuance of Purchase Shares to Selling 
 Shareholder (2)                                             |       |     | Proceeds from the